PepGen(PEPG) - 2025 Q2 - Quarterly Results

Clinical Trials - PepGen completed patient dosing in the 15 mg/kg cohort of the FREEDOM trial and is on track to report topline data in early Q4 2025[1] - The FREEDOM2 trial is set to transition clinical sites and is designed to demonstrate functional improvements with multiple doses of PGN-EDODM1[2] - PepGen anticipates reporting results from the 5 mg/kg cohort of the FREEDOM2 trial in Q1 2026[4] Financial Performance - Research and Development Expenses for Q2 2025 were $18.4 million, a decrease from $25.1 million in Q2 2024[8] - General and Administrative Expenses for Q2 2025 were $5.5 million, slightly up from $5.4 million in Q2 2024[8] - Net Loss for Q2 2025 was $23.1 million, or $(0.70) per share, compared to a net loss of $28.3 million, or $(0.87) per share, in Q2 2024[8] - Total operating expenses for Q2 2025 were $23.9 million, down from $30.4 million in Q2 2024[8] Cash and Assets - Cash, Cash Equivalents, and Marketable Securities were $74.7 million as of June 30, 2025, expected to fund operations into Q2 2026[8] - Total assets as of June 30, 2025, were $102.2 million, a decrease from $150.9 million at the end of 2024[8] Regulatory Designations - The company has received Orphan Drug and Fast Track Designations from the FDA for PGN-EDODM1[7]